New botulinum toxin aims to smooth frown lines in phase 2 trial
NCT ID NCT06481475
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new injection called YY003, a recombinant botulinum neurotoxin type A, for treating moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Participants receive a single set of small injections into five points between the brows. The trial measures how well the treatment reduces frown line severity and tracks any side effects, including immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YY003 (recombinant botulinum neurotoxin type A)
- What this could lead to
- If successful, YY003 could offer a new option for temporarily smoothing frown lines, potentially with fewer side effects than current botulinum toxin products.
- What could go wrong
- This is an early phase 2 study with only 149 participants, so results may not apply to everyone. As with any injection, risks include bruising, pain, or temporary muscle weakness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE GLABELLAR LINES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Institute of Victoria
Melbourne, Victoria, 3141, Australia
-
Skin Health Institute
Melbourne, Victoria, 3053, Australia
-
St George Dermatology & Skin Cancer Centre
Sydney, New South Wales, 2217, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.